ew-7197 and Precursor-Cell-Lymphoblastic-Leukemia-Lymphoma

Drug-resistant acute lymphoblastic leukemia (ALL) patients do not respond to standard chemotherapy, and an urgent need exists to develop new treatment strategies. Our study exploited the presence of B-cell activating factor receptor (BAFF-R) on the surface of drug-resistant B-ALL cells as a therapeutic target. We used anti-BAFF-R (VAY736), optimized for natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC), to kill drug-resistant ALL cells. VAY736 antibody and NK cell treatments significantly decreased ALL disease burden and provided survival benefit

Topics: Adult; Aniline Compounds; Animals; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Apoptosis; B-Cell Activation Factor Receptor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Killer Cells, Natural; Male; Mice; Mice, Inbred NOD; Mice, SCID; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Receptor, Transforming Growth Factor-beta Type I; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays